	US 12,011,453 B2
	Medicament for prevention or treatment of rhinovirus infection
Johannes Stockl, Vienna (AT); and Guido Gualdoni, Vienna (AT)
Assigned to MEDIZINISCHE UNIVERSITAT WIEN, Vienna (AT)
Filed by MEDIZINISCHE UNIVERSITAT WIEN, Vienna (AT)
Filed on Jul. 8, 2022, as Appl. No. 17/811,488.
Application 17/811,488 is a continuation of application No. 16/770,482, granted, now 11,413,298, previously published as PCT/EP2018/097060, filed on Dec. 28, 2018.
Claims priority of application No. 18154088 (EP), filed on Jan. 30, 2018.
Prior Publication US 2022/0362272 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7004 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61P 31/16 (2006.01)

CPC A61K 31/7004 (2013.01) [A61K 9/0043 (2013.01); A61K 9/0075 (2013.01); A61K 9/0078 (2013.01); A61K 9/008 (2013.01); A61K 45/06 (2013.01); A61P 31/16 (2018.01)]

19 Claims

1. A method, comprising:

obtaining a nasal spray containing a pharmaceutically acceptable formulation comprising 2-deoxy-D-glucose, wherein the concentration of 2-deoxy-D-glucose in the formulation is 0.1 mM-500 nM; and

spraying an amount of the formulation into one or both nostrils of a human individual,

wherein the individual has a condition selected from common cold caused by human rhinovirus (HRV) infection, asthma in combination with HRV infection and chronic obstructive pulmonary disease (COPD) in combination with HRV infection, or wherein the individual is at risk of developing a common cold caused by HRV infection.